subject articles if they were to be excluded;

(iv) indicate whether complainant, complainant's licensees, and/or third party suppliers have the capacity to replace the volume of articles potentially subject to the requested exclusion order and/or a cease and desist order within a commercially reasonable time; and

(v) explain how the requested remedial orders would impact United States consumers.

Written submissions on the public interest must be filed no later than by close of business, eight calendar days after the date of publication of this notice in the **Federal Register**. There will be further opportunities for comment on the public interest after the issuance of any final initial determination in this investigation. Any written submissions on other issues must also be filed by no later than the close of business, eight calendar days after publication of this notice in the **Federal Register**. Complainant(s) may file replies to any written submissions no later than three calendar days after the date on which the written submissions were due. Notwithstanding § 201.14(a) of the Commission's Rules of Practice and Procedure, the deadlines for written submissions and replies shall be counted by calendar days starting with the first calendar day following the **Federal Register** publication date or the due date for written submissions, respectively. The provisions of § 201.14(a) regarding the last day of the period still apply concerning the due date of any filings. No other submissions will be accepted, unless requested by the Commission. Any submissions and replies filed in response to this Notice are limited to five (5) pages in length, inclusive of attachments.

Persons filing written submissions must file the original document electronically on or before the deadlines stated above. Submissions should refer to the docket number (''Docket No. 3936'') in a prominent place on the cover page and/or the first page. (*See* Handbook for Electronic Filing Procedures, Electronic Filing Procedures [1]). Please note the Secretary's Office will accept only electronic filings unless an exemption is granted. Filings must be made through the Commission's Electronic Document Information System (EDIS, *https://edis.usitc.gov.*) Persons with questions regarding filing should contact the Secretary at *EDIS3Help@usitc.gov.*

Any person desiring to submit a document to the Commission in confidence must request confidential treatment. All such requests should be directed to the Secretary to the Commission and must include a full statement of the reasons why the Commission should grant such treatment. *See* 19 CFR 201.6. Documents for which confidential treatment by the Commission is properly sought will be treated accordingly. All information, including confidential business information and documents for which confidential treatment is properly sought, submitted to the Commission for purposes of this Investigation may be disclosed to and used: (i) by the Commission, its employees and Offices, and contract personnel (a) for developing or maintaining the records of this or a related proceeding, or (b) in internal investigations, audits, reviews, and evaluations relating to the programs, personnel, and operations of the Commission including under 5 U.S.C. Appendix 3; or (ii) by U.S. government employees and contract personne,[2] solely for cybersecurity purposes. All nonconfidential written submissions will be available for public inspection at the Office of the Secretary and on EDIS.[3]

This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and of §§ 201.10 and 210.8(c) of the Commission's Rules of Practice and Procedure (19 CFR 201.10, 210.8(c)).

By order of the Commission.

Issued: September 9, 2026.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2026–18644 Filed 9–11–26; 8:45 am]

BILLING CODE 7020–02–P

[1] Handbook for Electronic Filing Procedures: *https://www.usitc.gov/secretary/documents/handbook_on_filing_procedures.pdf.*

[2] All contract personnel will sign appropriate nondisclosure agreements.

[3] Electronic Document Information System (EDIS): *https://edis.usitc.gov.*

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337–TA–1495]

Certain Video-Capable Electronic Devices, Including Smart Televisions, Monitors, and Components Thereof; Notice of a Commission Determination Not To Review an Initial Determination Granting Dolby Laboratories, Inc.'s Motion To Intervene as an Intervenor

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has determined not to review the presiding administrative law judge's (''ALJ'') initial determination (''ID'') (Order No. 17) granting Dolby Laboratories, Inc.'s motion to intervene as an intervenor.

FOR FURTHER INFORMATION CONTACT: Lisa A. Murray, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205–2781. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission's electronic docket (EDIS) at *https://edis.usitc.gov.* For help accessing EDIS, please email *EDIS3Help@usitc.gov.* General information concerning the Commission may also be obtained by accessing its internet server at *https://www.usitc.gov.* Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal, telephone (202) 205–1810.

SUPPLEMENTARY INFORMATION: On April 2, 2026, the Commission instituted this investigation based on a complaint filed by InterDigital, Inc. of Wilmington, Delaware; InterDigital VC Holdings, Inc. of Wilmington, Delaware; and InterDigital Madison Patent Holdings SAS of Paris, France (collectively, ''InterDigital''). 91 FR 16743–44 (Apr. 2, 2026). The complaint alleged violations of section 337 based on the importation into the United States, the sale for importation, or the sale within the United States after importation of certain video-capable electronic devices, including smart televisions, monitors, and components thereof by reason of the infringement of certain claims of U.S. Patent No. 8,085,846 (the '846 patent''); U.S. Patent No. 9,294,784 (the '784 patent''); U.S. Patent No. 10,250,877 (the '877 patent''); U.S. Patent No. 11,695,962 (the '962 patent''); U.S. Patent No. 11,399,168 (the '168 patent''); and U.S. Patent No. 9,654,751 (the '751 patent''). *Id.* at 16743.

The Commission's notice of investigation named the following as respondents: TCL Industries Holdings Co., Ltd. of Guangdong, China; TCL Technology Group Corp. of Guangdong, China; TCL Electronics Holdings Limited of New Territories, Hong Kong; Shenzhen TCL New Technology Co., Ltd. of Guangdong, China; TCL King Electrical Appliances (Huizhou) Company, Limited of Huizhou, China; TCL Overseas Marketing Limited of New Territories, Hong Kong; TCL Smart

Device (Vietnam) Company, Limited of Binh Duong Province, Vietnam; TCL Smart Screen Technology HK of New Territories, Hong Kong; TCL Moka International Ltd. of New Territories, Hong Kong; TTE Technology, Inc. of Irvine, California; Hisense Co., Ltd. of Shandong Province, China; Hisense USA Corporation of Suwanee, Georgia; and Hisense Electronics Manufacturing Company of America Corporation of Suwanee, Georgia (collectively, ''Respondents''). The Office of Unfair Import Investigations is not participating in this investigation. *Id.* at 1674.

On July 10, 2026, non-party Dolby Laboratories, Inc. (''Dolby'') filed a motion pursuant to Commission Rule 210.19, 19 CFR 210.19, to intervene as an intervenor with full participation rights as to the '168 and '751 patents. On July 22, 2026, Complainants filed an opposition to the motion. Dolby filed a reply in support of its motion on July 27, 2026. While no other responses were received, Dolby certifies that the Respondents do not oppose the motion.

On August 12, 2026, the ALJ issued the subject ID (Order No. 17) granting Dolby's motion. The ALJ has determined that Dolby should be granted intervenor status in this investigation, but not status as a respondent. The ID states that Dolby's participation in this investigation should begin with the issuance of the subject ID and that Dolby may participate as an intervenor, including with respect to all claims and defenses at issue in the investigation regarding the '168 and '751 patents. No petitions for review were filed.

The Commission has determined not to review the subject ID. The Commission vote for this determination took place on September 9, 2026.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR Part 210).

By order of the Commission.

Issued: September 9, 2026.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2026–18715 Filed 9–11–26; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1763]

Importer of Controlled Substances Application: Irvine Labs, Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Irvine Labs, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on, or objections to the issuance of the proposed registration on or before October 14, 2026. Such persons may also file a written request for a hearing on the application on or before October 14, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on August 13, 2026, Irvine Labs, Inc., 7305 Murdy Circle, Huntington Beach, California 92647–3533, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Lysergic acid diethylamide.	7315	I
Marihuana Extract	7350	I
Marihuana	7360	I
Tetrahydrocannabinols	7370	I
Mescaline	7381	I
Peyote	7415	I
Diethyltryptamine	7434	I
Dimethyltryptamine	7435	I
Psilocybin	7437	I
Psilocyn	7438	I

The company plans to import bulk substances to support internal research, clinical trials, analytical purposes, and distribution to their customers. In reference to drug codes Marihuana Extract (7350), Marihuana (7360) and Tetrahydrocannabinols (7370), the company plans to import a raw plant material and extracts. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

Justin Wood,

Deputy Assistant Administrator.

[FR Doc. 2026–18757 Filed 9–11–26; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1759]

Bulk Manufacturer of Controlled Substances Application: Cambrex High Point, Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Cambrex High Point, Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before November 13, 2026. Such persons may also file a written request for a hearing on the application on or before November 13, 2026.